Reuters logo
BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11
November 10, 2017 / 12:59 PM / 12 days ago

BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11

Nov 10 (Reuters) - Vertex Pharmaceuticals Inc

* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below